

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 186 672 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
30.11.2005 Bulletin 2005/48

(51) Int Cl.7: **C12Q 1/68, C07K 14/47,
C07K 16/18**

(21) Application number: **01306983.6**

(22) Date of filing: **17.08.2001**

(54) **Polymorphisms in the human organic anion transporter C (OATP-C) gene**

Polymorphismen im Gen für den humanen organischen Anionentransporter C (OATP-C)

Polymorphismes dans le gène humain du transporteur d'anion organique (OATP-C)

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**

(30) Priority: **23.08.2000 US 226909 P**

(43) Date of publication of application:
13.03.2002 Bulletin 2002/11

(60) Divisional application:
05011183.0 / 1 589 115

(73) Proprietor: **AstraZeneca AB
151 85 Södertälje (SE)**

(72) Inventors:

- Adeokun, Monisola
Cheshire, SK10 4TG (GB)
- Ambrose, Helen Jean
Cheshire, SK10 4TG (GB)
- Cresswell, Carl John
Cheshire, SK10 4TG (GB)
- Dudley, Adam Jeston
Wilmington, DE 19850-5437 (US)

(74) Representative: **Giles, Allen Frank et al
AstraZeneca PLC
Global Intellectual Property
Mereside
Alderley Park
Macclesfield, Cheshire SK10 4TG (GB)**

(56) References cited:

WO-A-00/08157 WO-A-99/06046

- TAMAI I ET AL: "MOLECULAR IDENTIFICATION AND CHARACTERIZATION OF NOVEL MEMBERS OF THE HUMAN ORGANIC ANION TRANSPORTER (OATP) FAMILY" BIOCHIMICA ET BIOPHYSICA ACTA, AMSTERDAM, NL, vol. 273, no. 1, 2000, pages 251-260, XP000941538 ISSN: 0006-3002 & DATABASE EMBL [Online] EBI; 8 June 1999 (1999-06-08) TAMAI I ET AL.: "Homo sapiens mRNA for organic anion transporter OATP-C" retrieved from <HTTP://WWW.EBI.AC.UK/CGI-BIN/EMBLFETCH> Database accession no. AB026257
- DATABASE EMBL [Online] EBI; 2 February 2000 (2000-02-02) MUZNY DM ET AL.: "Homo sapiens 12p BAC RP11-12505" retrieved from <HTTP://WWW.EBI.AC.UK/CGI-BIN/EMBLFETCH> Database accession no. AC022335 XP002188259
- HSIANG B ET AL: "A NOVEL HUMAN HEPATIC ORGANIC ANION TRANSPORTING POLYPEPTIDE (OATP2)" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 52, 1999, pages 37161-37168, XP000877290 ISSN: 0021-9258
- ULBRECHT M ET AL.: "Assoziation of beta 2-adrenoreceptor variants with bronchial hyperresponsiveness" AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 161, no. 2, February 2000 (2000-02), pages 469-474, XP002188594

EP 1 186 672 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] This invention relates to polymorphisms in the human OATPC gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the OATPC gene, and to the use of OATPC polymorphism in treatment of diseases with OATPC transportable drugs.

[0002] Na⁺-independent organic anion transporting polypeptide (OATP) C gene is a member of the OATP supergene family involved in multifunctional transport of organic anion. OATPC transports the organic anion taurocholate, conjugated steroids: DHEAS, estradiol 17 β -D-glucoronide and estrone-3-sulfate, eicosanoids: PGE₂, thromboxane B₂, leukotriene C₄, and E₄, and thyroid hormones T4 and T3 1,2. OATPC has also been shown to be involved in the transport of xenobiotics, and drugs involved in lipid lowering e.g. statins¹. Statins have been referred to as a first-line therapy for patients with atherosclerotic vascular diseases. The OATPC gene and its product is also thought to be of importance in other diseases due to its transport of DHEAS an adrenal steroid which has been suggested to have positive neuropsychiatric, immune, and metabolic effects³. Due to the substrate specificity, location in the liver, and being exclusively expressed in the liver, Abe *et al* suggested that OATPC could be the predominant clearance mechanism of several endogenous and exogenous substrates in the liver. OATPC is the first human molecule reported to transport thyroid hormones².

[0003] This liver specific transporter may be useful in liver-specific drug delivery systems and liver-specific chemotherapy, bile acid formation and the pathogenesis of diseases such as cholestasis, hyperbilirubinemia and thyroid hormone resistance.

[0004] The OATPC gene (sometimes called OAPT2 in the literature) has been cloned by four different groups, annotated and published as EMBL accession numbers AB026257 (OATPC, 2452bp), AF205071(OATP2, 2830, ref 1), AJ132573(OATP2, 2778)⁴ and AF060500 (LST-1)². Polymorphism has been reported by Tamai⁵ which is Asn 130Asp and Val174Ala although any functional effect was stated therein to be not clear. Konig (2000) J Biol Chem 275, 23161-23168 describes the genomic organisation of OATP 1, 2 and 8. International patent application WO 00/08157 describes human anion transporter genes and some polymorphisms.

[0005] All positions herein of polymorphisms in the OATPC polynucleotide relate to the position in one of SEQ ID NO 1 or 3-12 unless stated otherwise or apparent from the context.

[0006] All positions herein of polymorphisms in the OATPC polypeptide relate to the position in SEQ ID NO 2 unless stated otherwise or apparent from the context.

[0007] One approach is to use knowledge of polymorphisms to help identify patients most suited to therapy with particular pharmaceutical agents (this is often termed "pharmacogenetics"). Pharmacogenetics can also be used in pharmaceutical research to assist the drug selection process. Polymorphisms are used in mapping the human genome and to elucidate the genetic component of diseases. The reader is directed to the following references for background details on pharmacogenetics and other uses of polymorphism detection: Linder *et al.* (1997), Clinical Chemistry, 43, 254; Marshall (1997), Nature Biotechnology, 15, 1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer *et al.* (1998), Nature Biotechnology, 16, 33.

[0008] Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. Thus there is a need for improved approaches to pharmaceutical agent design and therapy.

[0009] Point mutations in polypeptides will be referred to as follows: natural amino acid (using 1 or 3 letter nomenclature), position, new amino acid. For (a hypothetical) example "D25K" or "Asp25Lys" means that at position 25 an aspartic acid (D) has been changed to lysine (K). Multiple mutations in one polypeptide will be shown between square brackets with individual mutations separated by commas.

[0010] The present invention is based on the discovery of polymorphisms in OATPC.

[0011] According to one aspect of the present invention there is provided a method for the detection of a polymorphism in OATPC in a human, which method comprises determining the sequence of the human at:

position 1561 of the OATPC gene as defined by the position in SEQ ID NO: 1 is not G; or
position 488 in OATPC polypeptide defined by position in SEQ ID NO: 2 is not Gly.

[0012] The term human includes both a human having or suspected of having a OATPC mediated disease and an asymptomatic human who may be tested for predisposition or susceptibility to such disease. At each position the human may be homozygous for an allele or the human may be a heterozygote.

² Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1, Takaaki Abe *et al* J Biol Chem 274, 17159-17163 (1999)

³ A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2), Hslang *et al* J Biol Chem 274, 37161-37168 (1999)

⁴ Bates *et al* (1998) Curr. Opin. Endocrinol. Diab. 5, 357-366

⁴ A novel human organic anion transporting polypeptide localised to the basolateral hepatocyte membrane, Konig Jorg *et al* (2000) Am J Physiol. Gastrointest. Liver Physiol. 278: G156-G164

⁵ Tamai *et al* (2000), BBRC, 273, 251-60

- [0013] The term polymorphism includes single nucleotide substitution, nucleotide insertion and nucleotide deletion which in the case of insertion and deletion includes insertion or deletion of one or more nucleotides at a position of a gene.
- 5 [0014] The method for diagnosis is preferably one in which the sequence is determined by a method selected from amplification refractory mutation system and restriction fragment length polymorphism.
- [0015] The status of the individual may be determined by reference to allelic variation at any one, two, three, four, five, six, seven, eight, nine or more positions.
- 10 [0016] The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar lavage fluid, sputum, or other body fluid or tissue obtained from an individual. It will be appreciated that the test sample may equally be a nucleic acid sequence corresponding to the sequence in the test sample, that is to say that all or a part of the region in the sample nucleic acid may firstly be amplified using any convenient technique e.g. PCR, before analysis of allelic variation.
- 15 [0017] It will be apparent to the person skilled in the art that there are a large number of analytical procedures which may be used to detect the presence or absence of variant nucleotides at one or more polymorphic positions of the invention. In general, the detection of allelic variation requires a mutation discrimination technique, optionally an amplification reaction and optionally a signal generation system. Table 1 lists a number of mutation detection techniques, some based on the PCR. These may be used in combination with a number of signal generation systems, a selection of which is listed in Table 2. Further amplification techniques are listed in Table 3. Many current methods for the detection of allelic variation are reviewed by Nollau *et al.*, Clin. Chem. 43, 1114-1120, 1997; and in standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. Landegren, Oxford University Press, 1996 and "PCR", 2nd Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997.
- 20

Abbreviations:

25 [0018]

ALEX™	Amplification refractory mutation system linear extension
APEX	Arrayed primer extension
ARMS™	Amplification refractory mutation system
b-DNA	Branched DNA
bp	base pair
CMC	Chemical mismatch cleavage
COPS	Competitive oligonucleotide priming system
DGGE	Denaturing gradient gel electrophoresis
FRET	Fluorescence resonance energy transfer
HMG-CoA	3-hydroxy-3-methylglutaryl-coenzyme A
LCR	Ligase chain reaction
MASDA	Multiple allele specific diagnostic assay
NASBA	Nucleic acid sequence based amplification
OATP	Na ⁺ -independent organic anion transporting polypeptide
OLA	Oligonucleotide ligation assay
PCR	Polymerase chain reaction
PTT	Protein truncation test
RFLP	Restriction fragment length polymorphism
SDA	Strand displacement amplification
SNP	Single nucleotide polymorphism
SSCP	Single-strand conformation polymorphism analysis
SSR	Self sustained replication

(continued)

TGGE	Temperature gradient gel electrophoresis
------	--

5 Table 1 - Mutation Detection Techniques**[0019] General:** DNA sequencing, Sequencing by hybridisation**Scanning:** PTT*, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC, Enzymatic mismatch cleavage

* Note: not useful for detection of promoter polymorphisms.

10

Hybridisation Based**[0020] Solid phase hybridisation:** Dot blots, MASDA, Reverse dot blots,**Oligonucleotide arrays (DNA Chips)**

15

Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, 14, 303; WO 95/13399 (Public Health Inst., New York)**Extension Based:** ARMS™, ALEX™ - European Patent No. EP 332435 B1 (Zeneca Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, 17, 2347.

20

Incorporation Based: Mini-sequencing, APEX**Restriction Enzyme Based:** RFLP, Restriction site generating PCR**Ligation Based:** OLA**Other:** Invader assay

25

Table 2 - Signal Generation or Detection Systems**[0021] Fluorescence:** FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom

Patent No. 2228998 (Zeneca Limited)

Other: Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry

30

Table 3 - Further Amplification Methods**[0022]** SSR, NASBA, LCR, SDA, b-DNA**[0023]** Preferred mutation detection techniques include ARMS™, ALEX™, COPS, Taqman, Molecular Beacons, RFLP, and restriction site based PCR and FRET techniques.**[0024]** Particularly preferred methods include ARMS™ and RFLP based methods. ARMS™ is an especially preferred method.**[0025]** In a further aspect, the diagnostic methods of the invention are used to assess the pharmacogenetics of a drug transportable by OATPC.**[0026]** Assays, for example reporter-based assays, may be devised to detect whether one or more of the above polymorphisms affect transcription levels and/or message stability.**[0027]** Individuals who carry particular allelic variants of the OATPC gene may therefore exhibit differences in their ability to regulate protein biosynthesis under different physiological conditions and will display altered abilities to react to different diseases. In addition, differences arising as a result of allelic variation may have a direct effect on the response of an individual to drug therapy. The diagnostic methods of the invention may be useful both to predict the clinical response to such agents and to determine therapeutic dose.**[0028]** In a further aspect, the diagnostic methods of the invention, are used to assess the predisposition and/or susceptibility of an individual to diseases mediated by OATPC. This may be particularly relevant in the development of hyperlipoproteinemia and cardiovascular disease and the present invention may be used to recognise individuals who are particularly at risk from developing these conditions.**[0029]** In a further aspect, the diagnostic methods of the invention are used in the development of new drug therapies which selectively target one or more allelic variants of the OATPC gene. Identification of a link between a particular allelic variant and predisposition to disease development or response to drug therapy may have a significant impact on the design of new drugs. Drugs may be designed to regulate the biological activity of variants implicated in the disease process whilst minimising effects on other variants.**[0030]** In a further diagnostic aspect of the invention the presence or absence of variant nucleotides is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes.

55

[0031] According to another aspect of the present invention there is provided a human OATPC gene or its complementary strand comprising a variant allelic polymorphism at one or more of positions defined herein or a fragment thereof of at least 20 bases comprising at least one novel polymorphism.

[0032] Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

[0033] According to another aspect of the present invention there is provided a polynucleotide comprising at least 20 bases of the human OATPC gene and comprising an allelic variant selected from any one of the following:

Region	variant	Position in SEQ ID NO	SEQ ID NO
Exon 10	C	1561	1

[0034] According to another aspect of the present invention there is provided a human OATPC gene or its complementary strand comprising a polymorphism, preferably corresponding with one or more the positions defined herein or a fragment thereof of at least 20 bases comprising at least one polymorphism.

[0035] Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

[0036] The invention further provides a nucleotide primer which can detect a polymorphism of the invention.

[0037] According to another aspect of the present invention there is provided an ARMS allele specific primer or an allele-specific oligonucleotide probe selected from one of the following:

an ARMS allele specific primer;
or an allele-specific oligonucleotide probe;
capable of detecting a OATPC gene polymorphism, preferably at one or more of the positions as defined herein.

[0038] An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as a PCR reaction, which provides the discrimination between alleles through selective amplification of one allele at a particular sequence position e.g. as used for ARMS™ assays. The allele specific primer is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

[0039] An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3' terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4, 2, or 1 of the remaining nucleotides may be varied without significantly affecting the properties of the primer.

[0040] Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1st Edition. If required the primer(s) may be labelled to facilitate detection.

[0041] According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting a OATPC gene polymorphism, preferably at one or more of the positions defined herein.

[0042] The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

[0043] The design of such probes will be apparent to the molecular biologist of ordinary skill. Such probes are of any convenient length such as up to 50 bases, up to 40 bases, more conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such probes will comprise base sequences entirely complementary to the corresponding wild type or variant locus in the gene. However, if required one or more mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. The probes of the invention may carry one or more labels to facilitate detection.

[0044] According to another aspect of the present invention there is provided an allele specific primer or an allele specific oligonucleotide probe capable of detecting a OATPC gene polymorphism at one of the positions defined herein.

[0045] In another aspect of the invention, the single nucleotide polymorphisms of this invention may be used as genetic markers in linkage studies. This particularly applies to the polymorphisms of relatively high frequency. The OATPC gene is on chromosome 12p (as shown from a database search with the cDNA as a query sequence). Low frequency polymorphisms may be particularly useful for haplotyping as described below. A haplotype is a set of alleles found at linked polymorphic sites (such as within a gene) on a single (paternal or maternal) chromosome. If recombination within the gene is random, there may be as many as 2^n haplotypes, where 2 is the number of alleles at each SNP and n is the number of SNPs. One approach to identifying mutations or polymorphisms which are correlated with clinical response is to carry out an association study using all the haplotypes that can be identified in the population of interest. The frequency of each haplotype is limited by the frequency of its rarest allele, so that SNPs with low frequency alleles are particularly useful as markers of low frequency haplotypes. As particular mutations or polymorphisms associated with certain clinical features, such as adverse or abnormal events, are likely to be of low frequency

within the population, low frequency SNPs may be particularly useful in identifying these mutations (for examples see: Linkage disequilibrium at the cystathionine beta synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine. *Ann Hum Genet* (1998) **62**:481-90, De Stefano V, Dekou V, Nicaud V, Chasse JF, London J, Stansbie D, Humphries SE, and Gudnason V; and Variation at the von willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. *Blood* (1999) **93**:4277-83, Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D).

5 [0046] According to another aspect of the present invention there is provided use of a statin in preparation of a medicament for treating a cardiovascular disease in a human detected as having an OATPC polymorphism at one or
10 more of the following positions:

position 1561 of the OATPC gene as defined by the position in SEQ ID NO: 1 is not G;
position 488 in OATPC polypeptide defined by position in SEQ ID NO: 2 is not Gly.

15 [0047] Preferably determination of the status of the human is clinically useful. Examples of clinical usefulness include deciding which statin drug or drugs to administer and/or in deciding on the effective amount of the statin drug or drugs. Statins already approved for use in humans include atorvastatin, cerivastatin, fluvastatin, pravastatin and simvastatin. The reader is referred to the following references for further information: Drugs and Therapy Perspectives (12th May 1997), **9**: 1-6; Chong (1997) *Pharmacotherapy* **17**: 1157-1177; Kellick (1997) *Formulary* **32**: 352; Kathawala (1991)
20 Medicinal Research Reviews, **11**: 121-146; Jahng (1995) *Drugs of the Future* **20**: 387-404, and *Current Opinion in Lipidology*, (1997), **8**, 362 - 368. A preferred statin drug is compound 3a (S-4522) in Watanabe (1997) *Bioorganic and Medicinal Chemistry* **5**: 437-444; now called rosuvastatin, see Olsson (2001) *American Journal of Cardiology*, **87**, supplement 1, 33-36. The term "drug transportable by OATPC" means that transport by OATPC in humans is an important part of a drug exerting its pharmaceutical effect in man. For example, some statins have to be transported to the liver by OATPC to exert their lipid lowering effects.
25 [0048] According to another aspect of the present invention there is provided an allelic variant of human OATPC polypeptide comprising:

30 an arginine at position 488 of SEQ ID NO 2;
or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises at least one allelic variant.

[0049] Fragments of polypeptide are at least 10 amino acids, more preferably at least 15 amino acids, more preferably at least 20 amino acids.

35 [0050] The invention will now be illustrated but not limited by reference to the following Examples. All temperatures are in degrees Celsius.

[0051] In the Examples below, unless otherwise stated, the following methodology and materials have been applied.

[0052] AMPLITAQ™, available from Perkin-Elmer Cetus, is used as the source of thermostable DNA polymerase.

[0053] General molecular biology procedures can be followed from any of the methods described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989).

40 [0054] Electropherograms were obtained in a standard manner: data was collected by ABI377 data collection software and the wave form generated by ABI Prism sequencing analysis (2.1.2).

Example 1

45

Identification of Polymorphisms

1. Methods

50 DNA Preparation

[0055] DNA was prepared from frozen blood samples collected in EDTA following protocol I (Molecular Cloning: A Laboratory Manual, p392, Sambrook, Fritsch and Maniatis, 2nd Edition, Cold Spring Harbor Press, 1989) with the following modifications. The thawed blood was diluted in an equal volume of standard saline citrate instead of phosphate buffered saline to remove lysed red blood cells. Samples were extracted with phenol, then phenol/chloroform and then chloroform rather than with three phenol extractions. The DNA was dissolved in deionised water.

Template Preparation

[0056] Templates were prepared by PCR using the oligonucleotide primers and annealing temperatures set out below. The extension temperature was 72° and denaturation temperature 94°. Generally 50 ng of genomic DNA was used in each reaction and subjected to 35 cycles of PCR. Where described below, the primary fragment was diluted 1/100 and two microlitres were used as template for amplification of secondary fragments. PCR was performed in two stages (primary fragment then secondary fragment) to ensure specific amplification of the desired target sequence.

Polymorphisms in OATPC: cDNA screening of 15 Liver samples				
Region	SNP	Position	Amino Acid Change	Allele frequencies
Exon 4	G/A	510	None	G=96.7% A=3.3%
Exon 5	C/T	670	None	C=50% T=50%
Exon 5	C/T	696	None	C=60% T=40%
Exon 9	C/G	1299	Phe400Leu	C=96.7% G=3.3%
Exon 9	G/A	1312	Va1405Ile	G=96.7% A=3.3%
Exon 9	G/A	1347	None	G=96.7% A=3.3%
Exon 10	G/C	1561	Gly488Arg	G=96.7% C=3.3%
Exon 14	A/C	2028	Leu643Phe	A=90% C=10%

[0057] OATP2 above refers to the clone sequenced by Hsiang et al (ref 1). Some comment on the numbering of exons in OATPC is required. This gene contains an exon (38 bp upstream (5' UTR region) of the exon containing the ATG start site for translation. Therefore the exon numbering could vary depending whether this exon is counted as the first exon or not. In the literature, Konig (2000) JBC 275: 23161-68, have defined exon 1 as that containing the ATG start site and therefore we have adopted the same numbering in this application (but note that the priority document relating to the present application did vice versa; for example, exon 5 in this application is equivalent to exon 6 in the priority document).

PCR PRODUCTS		
Fragment	Forward Oligo	Reverse Oligo
443-999	443-466	979-999
874-1360	874-896	1337-1360
1255-1684	1255-1278	1663-1684
1559-2095	1559-1581	2073-2095

RFLP analysis			
Polymorphism	Position	RFLP Enzyme/PCR size	RFLP fragment size
G/A	510		

(continued)

RFLP analysis			
	Polymorphism	Position	RFLP Enzyme/PCR size
5	C/T	670	BmR I/ 595bp C=349bp, 246bp, T=595bp
	C/T	696	
10	C/G	1299	Apo I/ 595bp C=30bp, 60bp, 380 bp G=90bp, 380bp
	G/A	1312	Bst 4CI/ 595bp G=77bp, 393bp A=470bp
	G/A	1347	
15	G/C	1561	HpyCH4IV/ 595bp G=470bp C=144bp, 326bp
	A/C	2028	Ase I/ 595bp A=89bp, 488bp C=577bp
20			

Example 2

25 [0058]

30

35

40

45

50

55

Further OATPC Polymorphisms							
SNPs in OATPC 3'UTR (positions according to SEQ ID NO 1)							
	Exon	Nucleotide	SNP			Frequency	Frequency
						Caucasian	Japanese
5	3' UTR	2327	Ins T			not screened	0.1
10	3' UTR	2342	T>C			not screened	0.4
SNPs in OATPC promoter (positions according to SEQ ID NO 3)							
		Nucleotide	SNP			Frequency	Frequency
						Caucasian	Japanese
20		321	T>G			0.03	not screened
25		1332	A>C			0.08	not screened
SNPs in OATPC introns							
	Intron	Nucleotide	SNP	Nucleotide	Sequence		
						ID No	
30		position in relation to exon		position in sequence			
35	1	IVS1+21	T>A	41	4		
40	2	IVS2+89	T>G	109	5		
45	2	IVS2+224	A>G	244	5		
50	3	IVS3+97	C>A	117	6		
55	3	IVS3+263	G>A	283	6		
55	4	IVS4+189	G>A	209	7		
55	4	IVS4+191	G>A	211	7		
55	4	IVS5-118	delCTTGTA	63	8		
55	6	IVS6+33	C>T	53	9		
55	9	IVS10-107	ins TTC	75	10		
55	11	IVS11+142	Ins T	162	11		
55	12	IVS13-97	G>C	84	12		

OATPC intronic SNPs

55

Key

[0059] 20bp of exon sequence shown in uppercase

Intron sequence in lowercase (200 to 300bp only)
 SNP shown in uppercase (one allele only)

5 Sequence ID No 4
 IVS1+21 T>A

SNP at position 41 in this sequence

GATACTGC~~A~~ TGGATTGAAG gtaagaataag ttttatgttt Ttgagctaaa ataagtaaat 60
 agggactt aatgtataga aaagcaagtt gttaaaaaaga acattatgtt tcaaattata 120
 10 attttcaatt gaagcataata ttgaaatatt aacataatga ttcataccctt gatttaaacc 180
 agtcttttaa tctgattaag 200

15 Sequence ID No 5
 IVS2+89 T>G SNP at position 109 in this sequence
 IVS2+224 A>G SNP at position 244 in this sequence

TGACGGAA~~GC~~ TTTGAAATTG gtaacattta ttttctattt taataaccaa acttgcaaag 60
 ttaaaaaata tatatgc~~ttt~~ acaccactgg ttatcaactg gggtaaaatTt atctctcaca 120
 20 ggcaatttgg caataactaa aaacattt~~gt~~ ggttgtcata actgcacagg ggttggggc 180
 aatggaagt~~g~~ ctactggtat ctaaaggtag aggtcagggg tactgctaaa tattctataa 240
 tgcAcaaaga atgatgtAAC tgaaaatgtt gatagtgagg atgttcagaa accctgattc 300

25 Sequence ID No 6
 IVS3+97 C>A SNP at position 117 in this sequence
 IVS3+263 G>A SNP at position 283 in this sequence

30 CCACATTTCT TCATGGGATA gtaagtgtta aaaaaaaaaaa aaacctctgt gccactatca 60
 gtacctt~~gt~~a aattaggagt agaattttat tattatccct ttaaataggc agttacCttt 120
 tgagaagata cccacta~~gt~~ gtgtacagaa atgaaatagt gtctattt~~gt~~ ctacataatc 180
 atttattta tcgttagctt catatactt~~t~~ gaaataacaa aaagactaaa ctgttagagtt 240
 35 tcaa~~at~~gaaa taaatag~~gt~~ tttatgaat ttttagtata acGtata~~ta~~c t~~gt~~acgtctt 300

Sequence ID No 7
 40 IVS4+189 G>A SNP at position 209 in this sequence
 IVS4+191 G>A SNP at position 211 in this sequence

45 ACCTGAGATA GTGGGAAA~~AG~~ gtaagaatta atattgacag taaaag~~tct~~ tctaaaatgt 60
 atacatttaa ttacatctt aaaaattgtt gtgatattca ttagcaaaat ttaattaaga 120
 atgaatagga aaaacattt~~g~~ actcttacag acataattat agt~~tta~~ata tacacagttc 180
 gcccattaac aacacaggtt taaactacGc Gttttcactt ctatgcaaat tttgtccatc 240
 tgaactggat gataaac~~ct~~ ccg~~gt~~taagaa tatctgacat tttctatatt tggattgaac 300

50 Sequence ID No 8
 IVS5-118 delCTTGTA deletion of 6bp from position 63 to 68 incl.
 tagcagcata agaatggact aatacaccat attgtcaaag tttgcaaagt gaatataa~~at~~ 60
 taCTTGTA~~c~~ t~~gt~~taaattaa aaaaaataa g~~t~~agaataat taagagtta caagt~~gt~~ta 120
 aattt~~gt~~at agaaatgcta aaattaatgt taaaatgaa acactctt~~t~~ atctacatag 180
 GTTGT~~TT~~AAA GGAATCTGGG 200

Sequence ID No 9IVS6+33 C>T SNP at position 53 in this sequence
 TATTGGATAT GTAGATCTAA gtaagtacaa ccagaacaag gtaccatgat aaCgtcttcc 60
 taagcacaca tgcgaaaaac atttttcaa ataactgaat tcactcttc aatagtcctt 120
 tgcttaatat aattagaaag ttacaagttag gaaataaatg tattactaat cagaataaat 180
 ataaaaatcca getcttattt 200

5

Sequence ID No 10

IVS10-107 Ins TTC SNP at position 75 in this sequence
 taaaaaaaaa ctttgcatt tcgtcatcat caaagcaaat ttcttcatat aaagaaaaat 60
 tctttatcta cttt(TTC)ttttcc ctctttctct gcttcaact tacttttcc ttctcctccc 120
 cttctttgtc tttttcttct ctctctctct ttttgatata tgtctatcat atattccag 180
 AAATAATCCA GTGACATCTC 200

15

Sequence ID No 11

IVS11+142 Inst Inst at position 162 in this sequence

CATGTCATGC TGATTGTTAA gtaagtatga cttttaaaaa cattttcata tgcatgagac 60
 tataaacaca cctaatacgata tgcataattt tacataatat actggaaatt caaattcata 120
 tttcatcaaaa ttttaatttt ctgagaattc attttattaa aa(T)ttactatg aactctcaag 180
 gctgtaatta ataattttgc 200

25

Sequence ID No 12

IVS13-97 G>C SNP at position 84 in this sequence

tgatttgggt ctttgagatt tctaataatc ttttattattg gtagatgca gaacaaaata 60
 ataaacgaat cctccaaatt tttGaaactt tatttaatca aaatataatca atgtgaaata 120
 tcattgcattt acatttaaaa tatgttccct aaactgacat cttctttctt cctattacag 180
 GAGGAATTCT AGCTCCAATA 200

OATPC promoter region

35 [0060] Total length of the sequence = 1538bp

1500bp of OATPC sequence directly upstream from the cDNA sequence

Sequence in uppercase represents 38bp overlap with the cDNA sequence (SEQ ID NO 1) where this 38bp is 5'UTR sequence.

40 Nucleotide positions in the promoter have been determined where the -1 position is the base (lowercase) directly upstream of the end of the cDNA sequence.

45

50

55

atgcttttgc	acctctgaaa	atattggaga	attttacaac	tggcacccctt	agctcaggat	60
tataaagggt	gttagtttgt	ttgtactgtt	ttatcttcat	tgttatataat	atatatatta	120
gtctccaaac	atgttgatgt	gttttcaatg	aatggatgt	ctgaggagaa	aaccattagc	180
ctgagaaaaac	ccaaactgtta	ttcccattgt	gaataaaaagg	aagtccataa	aatatgtgaa	240
aaatgttctg	cattctgtt	atgatataca	aatctggcag	tacatgaaaa	tttttcaaag	300
tgcttattta	acaggcataa	tctttggct	cctgagccag	aatctgtcg	gtatgggact	360
ggattgtcat	tttgacaact	cccccagtga	ttcttactca	gcagagtatt	tggaagcctt	420
actctaataat	tttggccttg	ggtctacatt	tctcgttct	gcacatgtcat	tcttcccttc	480
tacactactc	tttagtttgt	ctcatgatcc	caatactctc	aataattaac	caagaataga	540
actaaatcaat	cagataactg	tggcacagac	atcaaataca	tttttgcgtca	accatataca	600
caaatgtccc	atgaatgata	aggggtaacc	atattctcat	atatgcatec	tcacattacc	660
acatataatat	atgtcataat	gtgtatcacg	gtaaaaatgt	gtatataatgt	atacatgtat	720
gtttgtgtgt	atatacataac	atatacttc	acacccccct	gaaaatataa	tatttatgtg	780
agagaagggt	ctgtacttta	tttcagaaga	gagcttaatg	tccaaggatg	aatttgcgtat	840
ctaaaatgtt	tgagttatgt	aattaattaa	acttcataatc	tactcaagaa	aacttttaac	900
tgaggttaagc	tcttcctttc	tccacaagtc	aagtcataaa	aaggaaaactg	tgatattaaat	960
aattctttcc	tgttttgatg	taaagaatct	atcgcataaaa	gcagttttaa	tttcatcat	1020
tcagaaaaat	ggtcttcgag	ttaatggga	ctcttttatt	ccaggtggta	tctccagttc	1080
ccatacatac	caaccttagaa	ccatacttat	gtaccaagaa	aaggggtat	attttataattt	1140
ttaaatgcca	atgtaacctg	taggcataatt	tttttattgt	cttaaattat	ttccttatttg	1200
gaagttttaa	ataccctggaa	taatttattg	tactcatatt	tttaaagaaa	aaaatcttat	1260
gccccaact	taatgtaaa	aacaagtaaa	agccatccc	aaaagtaagg	tttacttgtt	1320
aagattaaca	aaaataatg	tgagaattct	gagaataat	atctttaaat	attggcaact	1380
ggagtgaact	ctttaaaacta	actagttt	atatgtttga	ctagagcaat	gacataataa	1440
gggtggtaat	catcaactgga	cttggtttca	aaaagccaac	tactttaaaga	ggaataaaagg	1500
GTGGACTTGT	TGCAGTTGCT	GTAGGATTCT	AAATCCAG	1538		

25

SEQUENCE LISTING

[0061]

30

<110> AstraZeneca AB

<120> Chemical Compounds

35

<130> adeokun
ambrose
cresswell
dudley

40

<140>
<141>

<160> 12

45

<170> PatentIn Ver. 2.1

<210> 1
<211> 2452
<212> DNA

50

<400> 1

55

5 gtggacttgt tgcagttgtc gtaggattct aaatccagg tattgttca aactgagcat 60
 caacaacaaa aacatttgc tgatatctat atttcaatca tggaccaaaa tcaacatgg 120
 aataaaacag cagaggcaca acettcagag aataaaaaa caagatactg caatggattg 180
 aagatgttct tggcagctct gtcaactcgc ttattgtca agacactagg tgaattatt 240
 atgaaaagtt ccatacatca tatagaacgg agatggaga tatcccttc tcttgttgg 300
 ttattgtacg gaagcttga aattggaaat ttgcttgc tgatattgt gaggtaattt 360
 ggatccaaac tacatagacc aaagtttaatt ggaatcggtt gtttcaattt gggatttgg 420
 ggtgttttg ctgcgttgc acatttctt acggatattt acaggatttca aagaaaact 480
 aatatcaattt catcagaaaa ttcacatcg accttattcca ttgtttaat taatcaaatt 540
 ttatcaactca atagagacatc acctgagata gtggggaaaaag ttgtttaaa ggaatctggg 600
 tcatacatgt ggatatatgt ttcatgggt aatatgttcc ttggaaatgg ggagactccc 660
 atagtaccac tggggcttcc ttacattgtat gatttgccta aagaaggaca ttcttcttg 720
 tatttaggtt tattgaatgc aatagaatc attggtccaa tcattgcctt taccctggg 780
 tctctgtttt ctaaaatgtt cgtggatattt ggtatgtatg atctaagcac tattcaggata 840
 acrccactg attctcgatg ggtggagct ttgtggctt atttccctgt gtctggacta 900
 ttctccatta ttcttccat accattttt ttcttgcctt aaactccaaa taaaaccacaa 960
 aaagaaaagaa aagcttact gtcttgcat gtgtggaaa caaatgtga aaaggatcaa 1020
 acagctaattt tgaccaatca aggaaaaat attacccaaa atgtgactgg tttttccag 1080
 tcttttaaaa gcacccatc taatccccgtt tatttttatgt ttgtgtttt gacgttggta 1140
 caagtaagca gctatattgg tgctttact tatttttca aatacgtaga gcaacagtt 1200
 ggtcagccctt catctaaggc taacatcttta ttggggagtca taaccatacc tatttttgca 1260
 agtggaaatgtt ttttagggg atatattttttaaaaatttca aactgaacac cgttggattt 1320
 gccaaatttctt catgttttac tgctgtatg tattttctt tttacattt atatttttt 1380
 atactctgtt aaaaacaaatc agttggggca ctaaccatgtt cctatgtgg aataaattcca 1440
 gtgacatctc atagagatgtt accacttttctt tatttgcactt cagactgcaaa ttgtgtgaa 1500
 agtcaatggg aaccaggctg tggaaacaat ggaataactt acatcttacc ctgttttagca 1560
 ggttgcataat ttcacatgg caataaaaaag cctatgtgtt tttacaactg cagttgtttt 1620
 gaagtaactg gtctccagaa cagaaatttac tccacatcat tgggtgaatg cccaaagagat 1680
 gatgtttgtt caagggaaattt ttatttttt gttcaatc aagtcttggaa ttatttttt 1740
 tctgcacttgc gaggcacccatc acatgtatg tttttttttt tttttttttt tttttttttt 1800
 aataacttgc cactgggtt ccactcaatg gttatatacg cactaggagg aattttttttt 1860
 ccaatatattt ttggggctt gatttataca acgtgtatataa agtggccac caacaactgt 1920
 ggcacacgtt ggtcatgtatg gacatataat tccacatcat tttcaagggtt ctacttgggc 1980
 ttgtcttcaa ttgtttaatgtt tttttttttt tttttttttt tttttttttt tttttttttt 2040
 aagaaaaat atcaagagaa agatatcaat gcatcagaaaa atggaaatgtt catggatgaa 2100
 gcaaaacttag aatccataaa taaaataaaat cttttgtcc tttttttttt tttttttttt 2160
 gaaacacatc gttttaaggaa gaaaaaaagc cactttttttt tttttttttt tttttttttt 2220
 tgcatttgcatt cagttttttt ggtttttttt gttttttttt tttttttttt tttttttttt 2280
 cacatctttt atgggtggaaat tataaataatg cctatgtatc tttttttttt tttttttttt 2340
 gttagaaaaaa tgagagttttt tttttttttt tttttttttt tttttttttt tttttttttt 2400
 ctatatgtatc catacaatc aatgtttttt tttttttttt tttttttttt tttttttttt 2452

35

<210> 2
 <211> 691
 <212> PRT
 40 <213> Homo sapiens

<400> 2

45

50

55

Met Asp Gln Asn Gln His Leu Asn Lys Thr Ala Glu Ala Gln Pro Ser
 1 5 10 15

5 Glu Asn Lys Lys Thr Arg Tyr Cys Asn Gly Leu Lys Met Phe Leu Ala
 20 25 30

Ala Leu Ser Leu Ser Phe Ile Ala Lys Thr Leu Gly Ala Ile Ile Met
 35 40 45

10 Lys Ser Ser Ile Ile His Ile Glu Arg Arg Phe Glu Ile Ser Ser Ser
 50 55 60

Leu Val Gly Phe Ile Asp Gly Ser Phe Glu Ile Gly Asn Leu Leu Val
 65 70 75 80

15 Ile Val Phe Val Ser Tyr Phe Gly Ser Lys Leu His Arg Pro Lys Leu
 85 90 95

Ile Gly Ile Gly Cys Phe Ile Met Gly Ile Gly Gly Val Leu Thr Ala
 100 105 110

20 Leu Pro His Phe Phe Met Gly Tyr Tyr Arg Tyr Ser Lys Glu Thr Asn
 115 120 125

Ile Asn Ser Ser Glu Asn Ser Thr Ser Thr Leu Ser Thr Cys Leu Ile
 130 135 140

25 Asn Gln Ile Leu Ser Leu Asn Arg Ala Ser Pro Glu Ile Val Gly Lys
 145 150 155 160

Gly Cys Leu Lys Glu Ser Gly Ser Tyr Met Trp Ile Tyr Val Phe Met
 165 170 175

30 Gly Asn Met Leu Arg Gly Ile Gly Glu Thr Pro Ile Val Pro Leu Gly
 180 185 190

Leu Ser Tyr Ile Asp Asp Phe Ala Lys Glu Gly His Ser Ser Leu Tyr
 195 200 205

35 Leu Gly Ile Leu Asn Ala Ile Ala Met Ile Gly Pro Ile Ile Gly Phe
 210 215 220

Thr Leu Gly Ser Leu Phe Ser Lys Met Tyr Val Asp Ile Gly Tyr Val
 225 230 235 240

40 Asp Leu Ser Thr Ile Arg Ile Thr Pro Thr Asp Ser Arg Trp Val Gly
 245 250 255

Ala Trp Trp Leu Asn Phe Leu Val Ser Gly Leu Phe Ser Ile Ile Ser
 260 265 270

Ser Ile Pro Phe Phe Leu Pro Gln Thr Pro Asn Lys Pro Gln Lys
 275 280 285

45 Glu Arg Lys Ala Ser Leu Ser Leu His Val Leu Glu Thr Asn Asp Glu
 290 295 300

Lys Asp Gln Thr Ala Asn Leu Thr Asn Gln Gly Lys Asn Ile Thr Lys
 305 310 315 320

50 Asn Val Thr Gly Phe Phe Gln Ser Phe Lys Ser Ile Leu Thr Asn Pro
 325 330 335

Leu Tyr Val Met Phe Val Leu Leu Thr Leu Leu Gln Val Ser Ser Tyr
 340 345 350
 5 Ile Gly Ala Phe Thr Tyr Val Phe Lys Tyr Val Glu Gln Gln Tyr Gly
 355 360 365
 Gln Pro Ser Ser Lys Ala Asn Ile Leu Leu Gly Val Ile Thr Ile Pro
 370 375 380
 10 Ile Phe Ala Ser Gly Met Phe Leu Gly Gly Tyr Ile Ile Lys Lys Phe
 385 390 395 400
 Lys Leu Asn Thr Val Gly Ile Ala Lys Phe Ser Cys Phe Thr Ala Val
 405 410 415
 15 Met Ser Leu Ser Phe Tyr Leu Leu Tyr Phe Phe Ile Leu Cys Glu Asn
 420 425 430
 Lys Ser Val Ala Gly Leu Thr Met Thr Tyr Asp Gly Asn Asn Pro Val
 435 440 445
 20 Thr Ser His Arg Asp Val Pro Leu Ser Tyr Cys Asn Ser Asp Cys Asn
 450 455 460
 Cys Asp Glu Ser Gln Trp Glu Pro Val Cys Gly Asn Asn Gly Ile Thr
 465 470 475 480
 25 Tyr Ile Ser Pro Cys Leu Ala Gly Cys Lys Ser Ser Ser Gly Asn Lys
 485 490 495
 Lys Pro Ile Val Phe Tyr Asn Cys Ser Cys Leu Glu Val Thr Gly Leu
 500 505 510
 30 Gln Asn Arg Asn Tyr Ser Ala His Leu Gly Glu Cys Pro Arg Asp Asp
 515 520 525
 Ala Cys Thr Arg Lys Phe Tyr Phe Val Ala Ile Gln Val Leu Asn
 530 535 540
 35 Leu Phe Phe Ser Ala Leu Gly Gly Thr Ser His Val Met Leu Ile Val
 545 550 555 560
 Lys Ile Val Gln Pro Glu Leu Lys Ser Leu Ala Leu Gly Phe His Ser
 565 570 575
 40 Met Val Ile Arg Ala Leu Gly Gly Ile Leu Ala Pro Ile Tyr Phe Gly
 580 585 590
 Ala Leu Ile Asp Thr Thr Cys Ile Lys Trp Ser Thr Asn Asn Cys Gly
 595 600 605
 45 Thr Arg Gly Ser Cys Arg Thr Tyr Asn Ser Thr Ser Phe Ser Arg Val
 610 615 620
 Tyr Leu Gly Leu Ser Ser Met Leu Arg Val Ser Ser Leu Val Leu Tyr
 625 630 635 640
 Ile Ile Leu Ile Tyr Ala Met Lys Lys Tyr Gln Glu Lys Asp Ile
 645 650 655
 50 Asn Ala Ser Glu Asn Gly Ser Val Met Asp Glu Ala Asn Leu Glu Ser
 660 665 670
 Leu Asn Lys Asn Lys His Phe Val Pro Ser Ala Gly Ala Asp Ser Glu
 675 680 685
 55 Thr His Cys

5 <210> 3
 <211> 1538
 <212> DNA
 <213> Homo sapiens

10 <400> 3

atgctctttg acctctgaaa. atattggaga attttacaac tggcacctt agtcaggat 60
 tataaagggtt gttagtttgt ttgtactgtt ttatcttcat ttttatataat atatatatta 120
 gtcctccaaac atgttgatgt gtttcaatg aaatggatgt ctgaggagaa aaccattage 180
 15 ctgagaaaaac ccaaactgtt ttcccattgt gaataaaaagg aagtccataa aaatgtatgga 240
 aaatgttctg cattectgtt atgatataaa aatctggcag tacatgaaaa ttttcaaaag 300
 tgcttattta acaggcataa tcttggtct cctgagccag aatctgtgg gtatggact 360
 ggattgttat tttgacaact cgccagtaga ttcttactca gcagagtatt tggaaagcctt 420
 actctaataat tttggccctt ggtctacatt tctcagttct gcacagtcat tcttccccctc 480
 tacactactc tttagttgt ctcatgatcc caatactctc aataattaac caagaataga 540
 20 actaatcaat cagataactg tggcagacatc atcaataatac ttttgcgtca accatataaa 600
 caaatgtccc atgaatgata agggtaacc atattctcat atatgcattcc tcacattacc 660
 acatataataat atgtgcataat gtgtatacag gtaaaaagtgt gtatataatgt atacatgtat 720
 gtttgtgtgt atatacatac atataatctt acacttttct gaaatataata tattttatgtg 780
 agagaagggtt ctgtacttta tttcagaaga gagcttaatg tccaaggat aatttagaggt 840
 ctaaaatgtt tgagttattt aataattaa acttcattctc tactcaagaa aacttttaac 900
 tgagtttaagc tcttcatttc tccacaaggc aagtcaataa aaggaaactg tgatattaaat 960
 25 aattctttcc tggggatg taaaagatct atcgcataaa gcagtcttaa ttttcatcat 1020
 tcagaaaaat ggtcttgccat taaattggga ctcttattt ccagggtggta tctccagttct 1080
 ccatacatac cacgttagaa ccatacttat gtaccaagca aagagggtat attttatattt 1140
 taaaatgcca atgtaacctg taggcattatt ttttattttgt cttaaattat ttcctatattt 1200
 gaagttttaaa atacctggaa taatttattt tactcatatt tttaaagaaa aaaatcttat 1260
 gccaccaact taattgaata aacaagtaaa agccatcccc aaaagtaagg tttacttggtt 1320
 30 aagattaaca aaaaataatg tgagaattct gagaatata atctttaaat attggcaact 1380
 ggagtgaact cttaaaacta actaggttt atatgtttga cttagagcaat gacataataa 1440
 ggtggtaat catcaactgga ctgtttca aaaagccaaac tacttttaaga ggaataaagg 1500
 gtggacttgt tgcagttgtc ttaggattct aaatccag 1538

35 <210> 4
 <211> 200
 <212> DNA
 <213> Homo sapiens

40 <400> 4

.....
 45 gatactgcaa tggattgaag gtagaataag ttttatgttt ttgagctaaa ataagtaaat 60
 aggaacttt aatgtataga aaagcaagtt gtaaaaaaga acattatgtt tcaattata 120
 atttcaattt gaagcatata ttgaaatattt aacataatgtt ttcataccctt gatttaaacc 180
 agtcttttaa tctgattaag 200

50 <210> 5
 <211> 300
 <212> DNA
 <213> Homo sapiens

<400> 5

5 tgacggaagc tttgaaattt gtaacatTTA ttttctatt taataacca aacttgcAAAG 60
 ttaaaaaaaata tatATGCTT acaccACTgg ttatcaactg gggtaaattt atcttcaca 120
 ggcaatttgg caataactaa aaacATTGT ggttgtcata actgcacagg ggTTGGGGC 180
 aatggaaagtG ctactGGTat ctaaaggtag aggtcaggGGG tactGCTAAA tattctataa 240
 tgcacAAAGA atgatgtAAC tgAAATGTT gatagtGAGG atgttcAGAA accctgattc 300.

10 <210> 6
 <211> 300
 <212> DNA
 <213> Homo sapiens

15 <400> 6

20 ccacatttct tcATGGATA gtaAGTGTtA aaaaaaaaaaa aaACCTCTGT gCCACTATCA 60
 gtacCTTGTa aattAGGAGT agaATTtTA tattatCCCT ttaAAATAGGC agtTACCTT 120
 tgagaAGATA CCCACTAAGT gtGTACAGAA atgAAATAGT gtCTATTGT ctACATAATC 180
 atTTTATTTA tcGTAGCTT catATCTT gaaATAACAA aaAGACTAAA ctGTAGAGTT 240
 tcaAAATGAAA tAAATAGGCT ttttATGAAT ttttAGTATAc acgtatatac tGTACGTCTT 300

25

<210> 7
 <211> 300
 <212> DNA
 <213> Homo sapiens

<400> 7

30 acCTGAGATA gtggggAAAAG gtaAGAATTa atATTGACAG taaaaAGTCT tCTAAAATGT 60
 atacATTtAA ttACATCTCT AAAAATTGTT gtGATATTCA ttagAAAAT ttaATTAAAGA 120
 atGAATAGGA AAAACATTG ACTCTTACAG ACATAATTAT AGTGTAAATA tacACAGTTC 180
 GCCCATTAAC AACACAGGTT tAAACTACGC GTTTCACTT CTATGCAAAT tttgtccATC 240
 tGAACTGGAT gataAAACCTG CCGGTAAAGAA tATCTGACAT tttctatAtt tggattGAAC 300

35

<210> 8
 <211> 200
 <212> DNA
 <213> Homo sapiens

40 <400> 8

45 tagcAGCATA agaATGGACT aataCACCAT attGTCAAAG tttGCAAAGT gaATATAAAT 60
 tacttGtaCT tGTAATTAa aaaaaAAATAA gtagAAATAAT taAGAGTTA caAGTAGTTA 120
 aATTtGtaAT agAAATGCTA AAATTATGT ttaAAATGAA acACTCTCTT ATCTACATAG 180
 gttGTTAAA ggaATCTGGG 200

50

<210> 9
 <211> 200
 <212> DNA
 <213> Homo sapiens

<400> 9

55

tattGGATAT gtagatCTAA gtaAGTACAA ccAGAACAAAG gtACCAtGAT aACGTCTTTC 60
 taAGCACACA tGCGAAAAAC attTTTCAAT aTAACtGAAT tcACTCTTTC AATAGTCCTT 120
 tgCTTAATAT aATTAGAAAG ttACAAGTAG gAAATAAATG tATTACTAAT cAGAAATAAT 180
 ataAAATCCA gCTCCTATTt 200

<210> 10
<211> 203
<212> DNA
<213> Homo sapiens

5

<400> 10

10 taaaaaaaaa ctgtccatt tcgtcatcat caaagcaaat ttcttcataat aaagaaaaat 60
 tcttttatcta ctttttcttt tcccttttc tctgcttca ctttactttctt tccttctcct 120
 ccccttcctt gtcttttctt tctctcttc tcttttgat atatgtctat catatatttc 180
 cagaaaaataat ccagtgcacat ctc 203

10

<210> 11

15

<212> DNA

<213> *Homo sapiens*

-1400- 11

28

```
catgtcatgc tgattgttaa gtaagtatga cttttaaaaa cattttcata tgcatgagac 60  
tataaacaca ccttaatgata tgcataatcc tacataaat actggaaatt caaattcata 120  
tttcatcaaa tttaatttt ctgagaattc attttattaa aatttactat gaactctcaa 180  
ggctgttaatt aataattttt c
```

25

<210> 12

30

<211> 200

<212> DNA

<213> Homo sapiens

<400> 12

35

tgtatgggt ctttgagatt tctaataatc ttattatttg ggttagatgca gaacaaaata 60
ataaacgaat cctccaaattt ttgaacttt tatattaatca aaatatataca atgtgaaata 120
tcatgcgtt acataaaaaa tatgttccct aaactgacat ctctcttct cctattacag 180
gaggaattct agctccaata. 200

40

Claims

45

1. A method for the detection of a polymorphism in OATPC in a human, which method comprises determining the sequence of the human at:

position 1561 of the OATPC gene as defined by the position in SEQ ID NO: 1 is not G; or position 488 in OATPC polypeptide defined by position in SEQ ID NO: 2 is not Gb.

- ### **2. Use of a method as defined in claim 1 to prepare the product**

- ### 3. A polynucleotide comprising a telomeric GCA sequence at its 3' end

55

Region	variant	Position in SEQ ID NO	SEQ ID NO
Exon 10	C	1561	1

4. An ARMS allele specific primer or an allele-specific oligonucleotide probe selected from one of the following:

- 5 an ARMS allele specific primer; or
 an allele-specific oligonucleotide probe,
 capable of detecting a OATPC gene polymorphism as defined in claim 1.

5 5. Use of an OATPC polymorphism as defined in claim 1 as a genetic marker in a linkage study.

10 6. Use of a statin in preparation of a medicament for treating a cardiovascular disease in a human detected as having
 an OATPC polymorphism at one or more of the following positions:

- position 1561 of the OATPC gene as defined by the position in SEQ ID NO: 1 is not G;
 position 488 in OATPC polypeptide defined by position in SEQ ID NO: 2 is not Gly.

15 7. A use according to claim 6 in which the drug is rosuvastatin.

8. An allelic variant of human OATPC polypeptide comprising;
 an arginine at position 488 of SEQ ID NO 2
 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant.

20

Patentansprüche

1. Verfahren zum Nachweis eines Polymorphismus in OATPC in einem Menschen, wobei man in dem Verfahren
 25 bestimmt, daß die Sequenz des Menschen in:

Position 1551 des OATPC-Gens, wie durch die Position in SEQ ID NO: 1 definiert, nicht G ist; oder
 Position 488 im OATPC-Polypeptid, definiert durch die Positionen in SEQ ID NO: 2, nicht Gly ist.

30 2. Verwendung eines Verfahrens gemäß Anspruch 1 zur Beurteilung der Pharmacogenetik eines durch OATPC trans-
 portierbaren Arzneistoffs.

35 3. Polynukleotid, umfassend wenigstens 20 Basen des menschlichen OATPC-Gens und umfassend die Allelvariante:

Region	Variante	Position in SEQ ID NO:	SEQ ID NO:
Exon 10	C	1561	1

40 4. ARMS-Allel-spezifischer Primer oder Allelspezifische Oligonukleotidsonde, ausgewählt aus einem der folgenden
 Moleküle:

45 einem ARMS-Allel-spezifischen Primer; oder
 einer Allel-spezifischen Oligonukleotidsonde,
 womit ein OATPC-Gen-Polymorphismus gemäß Anspruch 1 nachgewiesen werden kann.

50 5. Verwendung eines OATPC-Polymorphismus gemäß Anspruch 1 als genetischer Marker in einer Verknüpfungsuntersuchung.

55 6. Verwendung eines Statins bei der Herstellung eines Arzneimittels zur Behandlung einer Herzkreislauferkrankung
 in einem Menschen, bei dem ein OATPC-Polymorphismus an einer oder mehreren der folgenden Positionen nach-
 gewiesen wurde:

Position 1561 des OATPC-Gens, wie durch die Positionen in SEQ ID NO: 1 definiert, ist nicht G;
 Position 488 im OATPC-Polypeptid, definiert durch die Positionen in SEQ ID NO: 2, ist nicht Gly.

55 7. Verwendung nach Anspruch 6, wobei es sich bei dem Arzneistoff um Rosuvastatin handelt.

8. Allelvariante des menschlichen OATPC-Polypeptids, umfassend:

ein Arginin in Position 488 der SEQ ID NO: 2
 oder ein Fragment davon, umfassend wenigstens 10 Aminosäuren, vorausgesetzt, daß das Fragment die Allelvariante umfaßt.

5

Revendications

1. Procédé pour la détection d'un polymorphisme dans un OATPC d'un être humain, lequel procédé comprend l'étape consistant à déterminer la séquence de l'humain au niveau de :

10

la position 1561 du gène d'OATPC, comme cela est défini par la position dans la SEQ ID n° : 1, qui n'est pas un G ; ou
 la position 488 dans un polypeptide d'OATPC, définie par la position dans la SEQ ID n° : 2, qui n'est pas une Gly.

15

2. Utilisation d'un procédé, comme cela est défini à la revendication 1, pour évaluer les aspects pharmacogénétiques d'une substance médicamenteuse pouvant être transportée par un OATPC.

3. Polynucléotide comprenant au moins 20 bases du gène d'OATPC humain et comprenant le variant allélique :

20

Région	Variant	Position dans la SEQ ID n° :	SEQ ID n° :
Exon 10	C	1561	1

- 25 4. Amorce spécifique d'un allèle ARMS ou sonde oligonucléotidique spécifique d'un allèle choisie parmi l'un des éléments suivants :

une amorce spécifique d'un allèle ARMS ; ou
 une sonde oligonucléotidique spécifique d'un allèle,
 30 capable de détecter un polymorphisme dans un gène d'OATPC, comme cela est défini à la revendication 1.

5. Utilisation d'un polymorphisme d'OATPC, comme cela est défini à la revendication 1, en tant que marqueur génétique dans une étude de liaison.

- 35 6. Utilisation d'une statine dans la préparation d'un médicament destiné à traiter une affection cardiovasculaire chez un être humain, chez qui on a détecté un polymorphisme d'OATCP au niveau d'une ou plusieurs positions parmi les suivantes :

la position 1561 du gène d'OATPC, comme cela est défini par la position dans la SEQ ID n° : 1, n'est pas un G ; ou
 40 la position 488 dans un polypeptide d'OATPC, définie par la position dans la SEQ ID n° : 2, n'est pas une Gly.

7. Utilisation selon la revendication 6, dans laquelle la substance médicamenteuse est la rosuvastatine.

- 45 8. Variant allélique d'un polypeptide d'OATPC humain comprenant :

une arginine à la position 488 de la SEQ ID n° : 2 ou un fragment de celle-ci comprenant au moins 10 acides aminés, à condition que le fragment comprenne le variant allélique.

50

55